Immuno-targeting of pancreatic cancer stem cells

Pancreatic cancer is a highly aggressive and deadly disease harboring a distinct population of cancer stem cells (CSC) that is not affected by conventional therapies. A new therapeutic approach using the EpCAM/CD3-bispecific antibody MT110 is capable of activating and redirecting cytotoxic T cells to eliminate primary human pancreatic cancer stem cells, which resulted in long-term survival of preclinical xenografts models.

• Publication year

  2012

• Venue

  Oncoimmunology

• Publication date

  2012-07-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.4161/onci.19368PMID 22754787PMCID 3382890
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Nodal/Activin signaling drives self-renewal and tumorigenicity of pancreatic cancer stem cells and provides a target for combined drug therapy.

  2011cited by this paper
• EpCAM/CD3-Bispecific T-cell Engaging Antibody MT110 Eliminates Primary Human Pancreatic Cancer Stem Cells

  2011cited by this paper
• Targeting ALDHbright Human Carcinoma–Initiating Cells with ALDH1A1-Specific CD8+ T Cells

  2011cited by this paper
• Cancer Statistics, 2010

  2010cited by this paper
• The emerging role of EpCAM in cancer and stem cell signaling.

  2009cited by this paper
• Combined targeted treatment to eliminate tumorigenic cancer stem cells in human pancreatic cancer.

  2009cited by this paper
• The epithelial-mesenchymal transition generates cells with properties of stem cells.

  2008cited by this paper
• Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer.

  2007cited by this paper
• Gemcitabine combined with continuous infusion 5-fluorouracil in advanced and symptomatic pancreatic cancer: a clinical benefit-oriented phase II study

  2000cited by this paper
• A cell initiating human acute myeloid leukaemia after transplantation into SCID mice

  1994cited by this paper
• Cancer statistics

  1989cited by this paper

• Bispecific T cell engagers and their synergistic tumor immunotherapy with oncolytic viruses.

  2021cites this paper
• Tumorspheres as an in vitro model for cancer stem-like cell characterization in non-small cell lung cancer. Prognostic implications

  2020cites this paper
• EpCAM duality becomes this molecule in a new Dr. Jekyll and Mr. Hyde tale.

  2018cites this paper
• Recent advances of bispecific antibodies in solid tumors

  2017cites this paper
• Adjuvant therapy for resectable pancreatic adenocarcinoma: review of the current treatment approaches and future directions.

  2014cites this paper
• Immune-based therapies in pancreatic and colorectal cancers and biomarkers of responsiveness

  2014cites this paper
• Untersuchung des Zelloberflächenmoleküles Epithelial Cell Adhesion Molecule (EpCAM) als prognostischer Marker beim duktalen Adenokarzinom des Pankreas

  2013cites this paper
• Cancer T cell immunotherapy with bispecific antibodies and chimeric antigen receptors.

  2013cites this paper
• Stem cells & pancreatic cancer.

  2013cites this paper